The medtech sector experienced 706 funding deals encompassing $5.8 billion in venture capital investments in 2016, down from 676 deals of $6.42 billion in 2015. By contrast, 2014 boasted 800 funding deals comprising $6.8 billion.
To address dwindling investment in medical devices, companies should engage in strategic partnerships and co-development initiatives, according to the report. In 2016, the plurality of co-development activity in the medtech sector — 45 percent — related to in-vitro diagnostics.
Other co-development partners hailed from health IT (19 percent), diabetes care device (5 percent) and cardiovascular device (3 percent) sectors, among others.
To access the full report, click here.
More articles on supply chain:
Philips to suspend some defibrillator manufacturing in US: 5 things to know
FDA approves record number of generics in FY 17
Consumers view drugs as less risky when more side effects are listed in ads
